FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 360:2367-2370 May 28, 2009 Number 22 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Gnant, M. PubMed Citation

To the Editor: Gnant et al. (Feb. 12 issue)¹ report on the Austrian Breast and Colorectal Cancer Study Group trial 12 (ABCSG-12) (ClinicalTrials.gov number, NCT00295646 [ClinicalTrials.gov] ), which looked at the use of goserelin plus either tamoxifen or anastrozole with or without zoledronic acid in premenopausal women with breast cancer. The authors conclude that the addition of zoledronic acid improved disease-free survival and that treatment with tamoxifen and treatment with anastrozole were associated with similar rates of disease-free survival. However, a separate analysis of the group of patients who received anastrozole without zoledronic acid would be of interest.

Frederik Wenz, M.D.
. . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.